Diflunisal versus tafamidis on neuropathy and cardiomyopathy in hereditary transthyretin amyloidosis
Annals of Clinical and Translational Neurology · 2024
DOI: 10.1002/acn3.52158 ↗Kurz gefasst
Vergleichsstudie in der Zeitschrift Annals of Clinical and Translational Neurology, 2024. Verfasst von Chi-Chao Chao und 13 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurology, National Taiwan University Hospital, Taipei, Taiwan. Hauptthemen laut MEDLINE: Diflunisal, Amyloid Neuropathies, Familial, Cardiomyopathies, Benzoxazoles. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 44 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Ministry of Science and Technology, Taiwan, National Taiwan University Hospital, National Science and Technology Council.
Abstract (Originalsprache)
Objectives
Hereditary transthyretin (TTR) amyloidosis (ATTRv) is frequently complicated by polyneuropathy (ATTRv‐PN) and cardiomyopathy (ATTRv‐CM). The long‐term efficacy of diflunisal on both polyneuropathy and cardiomyopathy in ATTRv patients, especially those with non‐V30M genotypes, has not been fully investigated and compared with that of tafamidis.
Methods
We compared the structural and biochemical characteristics of A97S‐TTR complexed with tafamidis with those of diflunisal, and prospectively followed up and compared the progression of polyneuropathy and cardiomyopathy between ATTRv‐PN patients taking diflunisal and those taking tafamidis.
Results
Both diflunisal and tafamidis effectively bind to the two thyroxine‐binding sites at the A97S‐TTR dimer–dimer interface and equally and almost sufficiently reduce amyloid fibril formation. Thirty‐five ATTRv‐PN patients receiving diflunisal and 22 patients receiving tafamidis were enrolled. Compared with no treatment, diflunisal treatment significantly delayed the transition of FAP Stage 1 to 2 and Stage 2 to 3 and decreased the deterioration in parameters of the ulnar nerve conduction study (NCS). The progression of FAP stage or NCS parameters did not differ between patients treated with diflunisal and those treated with tafamidis. Both diflunisal and tafamidis treatments significantly decreased radiotracer uptake on 99m Tc‐PYP SPECT and stabilized cardiac wall thickness and blood pro‐B‐type natriuretic peptide levels. No significant adverse events occurred during diflunisal or tafamidis treatment. Interpretations The binding patterns of both tafamidis and diflunisal to A97S‐TTR closely resembled those observed in the wild type. Diflunisal can effectively delay the progression of polyneuropathy and cardiomyopathy with similar efficacy to tafamidis and may become a cost‐effective alternative treatment for late‐onset ATTRv‐PN.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Neurology, National Taiwan University Hospital, Taipei, Taiwan.
- Institute of Biochemistry and Molecular Biology, College of Medicine, National Taiwan University, Taipei, Taiwan.
- Department of Biomedical Engineering, National Yang Ming Chiao Tung University, Taipei, Taiwan.
- Department of Medicine, National Yang Ming Chiao Tung University, Taipei, Taiwan.
- Department of Nuclear Medicine, National Taiwan University Hospital, Taipei, Taiwan.
- Department of Internal Medicine, National Taiwan University Hospital, Taipei, Taiwan.
ORCID-Profile: Chi-Chao Chao, Shiou-Ru Tzeng, Ming-Chang Chiang, Hsueh-Wen Hsueh, Sung-Tsang Hsieh
Förderung
- Ministry of Science and Technology, Taiwan
- National Taiwan University Hospital
- National Science and Technology Council
Zitieren
APA
Chao, C. C., Tzeng, S. R., Chiang, M. C., Hsueh, H. W., Hsieh, W. J., Chao, Y. C., Cheng, M. F., Lin, Y. H., Su, M. Y., Huang, C. H., Wang, Y. S., Hsieh, M. F., Tseng, P. H., & Hsieh, S. T. (2024). Diflunisal versus tafamidis on neuropathy and cardiomyopathy in hereditary transthyretin amyloidosis. Annals of Clinical and Translational Neurology. https://doi.org/10.1002/acn3.52158
Vancouver
Chao CC, Tzeng SR, Chiang MC, Hsueh HW, Hsieh WJ, Chao YC, et al. Diflunisal versus tafamidis on neuropathy and cardiomyopathy in hereditary transthyretin amyloidosis. Annals of Clinical and Translational Neurology. 2024. doi:10.1002/acn3.52158
BibTeX
@article{Chao2024,
author = {Chao, Chi-Chao and Tzeng, Shiou-Ru and Chiang, Ming-Chang and Hsueh, Hsueh-Wen and Hsieh, Wan-Jen and Chao, Yuan-Chun and Cheng, Mei-Fang and Lin, Yen-Hung and Su, Mao-Yuan and Huang, Chun-Hsiang and Wang, Yi-Shiang and Hsieh, Ming-Fang and Tseng, Ping-Huei and Hsieh, Sung-Tsang},
title = {Diflunisal versus tafamidis on neuropathy and cardiomyopathy in hereditary transthyretin amyloidosis},
journal = {Annals of Clinical and Translational Neurology},
year = {2024},
doi = {10.1002/acn3.52158}
}
EUVIMED